Rate and Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation: Current Status

Author(s): Eleonora Russo*, Domenico R. Potenza, Michela Casella, Raimondo Massaro, Giulio Russo, Maurizio Braccio, Antonio Dello Russo, Mauro Cassese.

Journal Name: Current Cardiology Reviews

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Transcather aortic valve implantation (TAVI) has become a safe and indispensable treatment option for patients with severe symptomatic aortic stenosis who are at high surgical risk. Recently, outcomes after TAVI have improved significantly and TAVI has emerged as a qualified alternative to surgical aortic valve replacement in the treatment of intermediate risk patients and greater adoption of this procedure is to be expected in a wider patients population, including younger patients and low surgical risk patients. However since the aortic valve has close spatial proximity to the conduction system, conduction anomalies are frequently observed in TAVI. In this article, we aim to review the key aspects of pathophysiology, current incidence, predictors and clinical association of conduction anomalies following TAVI.

Keywords: Transcatheter aortic valve implantation, pacemaker implantation, predictive factors, left bundle branch block, review, valve in valve transcatheter aortic valve implantation, electrophysiological study.

[1]
Smith CR, Leon MB, Mack MJ, et al. PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187-98.
[2]
Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC 2017 Focused Update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70(2): 252-89.
[3]
De Torres-Alba F, Kaleschke G, Diller GP, et al. Changes in the pacemaker rate after transition from edwards sapien xt to sapien 3 transcatheter aortic valve implantation: The critical role of valve implantation height. JACC Cardiovasc Interv 2016; 9(8): 805-13.
[4]
Husser O, Pellegrini C, Kessler T, et al. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 2016; 9(3): 244-54.
[5]
Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation 2010; 121(16): 1848-57.
[6]
Silaschi M, Wendler O, Seiffert M, et al. Transcatheter valve in-valve implantation versus redo surgical aortic valve replacement in patients with failed aortic bioprostheses. Interact Cardiovasc Thorac Surg 2017; 24(1): 63-70.
[7]
Kawashima T, Sato F. Visualizing anatomical evidences on atrio ventricular conduction system for TAVI. Int J Cardiol 2014; 174(1): 1-6.
[8]
Lange P, Greif M, Vogel A, et al. Reduction of pacemaker implantation rates after CoreValve® implantation by moderate predilatation. EuroIntervention 2014; 9(10): 1151-7.
[9]
Auffret V, Regueiro A, Campelo-Parada F, et al. Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: A systematic review and meta- analysis. Catheter Cardiovasc Interv 2017; 90(5): 839-50.
[10]
Martin GP, Sperrin M, Bagur R, et al. Pre-implantation balloon aortic valvuloplasty and clinical outcomes following transcatheter aortic valve implantation: A propensity score analysis of the UK registry. J Am Heart Assoc 2017; 6(2): pii e004695.
[11]
Rogers T, Waksman R, Harrison JK, et al. Impact of balloon predilatation on hemodynamics and outcomes after transcatheter aortic valve implantation with the self-expanding corevalve prosthesis. Am J Cardiol 2018; 121(11): 1358-64.
[12]
Al-Azzam F, Greason KL, Krittanawong C, et al. The influence of native aortic valve calcium and transcatheter valve oversize on the need for pacemaker implantation after transcatheter aortic valve insertion. J Thorac Cardiovasc Surg 2017; 153(5): 1056-62.
[13]
Lefèvre T, Kappetein AP, Wolner E, et al. PARTNER EU Investigator Group. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur Heart J 2011; 32(2): 148-57.
[14]
Abdel-Wahab M, Mehilli J, Frerker C, et al. CHOICE investigators. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: The CHOICE randomized clinical trial. JAMA 2014; 311(15): 1503-14.
[15]
Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv 2010; 3(4): 359-66.
[16]
van Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: A systematic review. Eur Heart J 2018; 39(21): 2003-13.
[17]
Nijhoff F, Abawi M, Agostoni P, Ramjankhan FZ, Doevendans PA, Stella PR. Transcatheter aortic valve implantation with the new balloon-expandable Sapien 3 versus Sapien XT valve system: A propensity score-matched single-center comparison. Circ Cardiovasc Interv 2015; 8(6): e002408.
[18]
Wendler O, Schymik G, Treede H, et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. Eur Heart J 2017; 38(36): 2717-26.
[19]
Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: Results of the Evolut R U.S. study. JACC Cardiovasc Interv 2017; 10(3): 268-75.
[20]
Giannini C, De Carlo M, Tamburino C, et al. Transcathether aortic valve implantation with the new repositionable self-expandable Evolut R versus CoreValve system: A case-matched comparison. Int J Cardiol 2017; 243: 126-31.
[21]
Möllmann H, Walther T, Siqueira D, et al. Transfemoral TAVI using the self-expanding ACURATE neo prosthesis: One-year outcomes of the multicentre “CE-approval cohort”. EuroIntervention 2017; 13(9): e1040-6.
[22]
Meredith IT, Worthley SG, Whitbourn RJ, et al. Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: The REPRISE I study. EuroIntervention 2014; 9(11): 1264-70.
[23]
Meredith IT, Walters DL, Dumonteil N, et al. 1-year outcomes with the fully repositionable and retrievable lotus transcatheter aortic replacement valve in 120 high-risk surgical patients with severe aortic stenosis: Results of the REPRISE II study. JACC Cardiovasc Interv 2016; 9(4): 376-84.
[24]
Giannini F, Latib A, Montorfano M, et al. A comparison of the fully repositionable and retrievable Boston Lotus and direct flow medical valves for the treatment of severe aortic stenosis: A single center experience. Catheter Cardiovasc Interv 2018; 91(5): 966-74.
[25]
Naber CK, Pyxaras SA, Ince H, et al. A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aortic stenosis. EuroIntervention 2016; 12(11): e1413-9.
[26]
Silaschi M, Conradi L, Wendler O, et al. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv 2018; 91(7): 1345-51.
[27]
Möllmann H, Linke A, Holzhey DM, et al. Implantation and 30-day follow-up on all 4 valve sizes within the portico transcatheter aortic bioprosthetic family. JACC Cardiovasc Interv 2017; 10(15): 1538-47.
[28]
Walther T, Manoharan G, Linke A, et al. Incidence of new-onset left bundle branch block and predictors of new permanent pacemaker following transcatheter aortic valve replacement with the Portico™ valve. Eur J Cardiothorac Surg 2018; 54(3): 467-74.
[29]
Tzamtzis S, Viquerat J, Yap J, Mullen MJ, Burriesci G. Numerical analysis of the radial force produced by the Medtronic-CoreValve and Edwards-SAPIEN after transcatheter aortic valve implantation (TAVI). Med Eng Phys 2013; 35(1): 125-30.
[30]
Meredith Am IT, Walters DL, Dumonteil N, et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol 2014; 64(13): 1339-48.
[31]
van Gils L, Tchetche D, Lhermusier T, et al. Transcatheter heart valve selection and permanent pacemaker implantation in patients with pre-existent right bundle branch block. J Am Heart Assoc 2017; 6(3): pii e005028.
[32]
Mauri V, Reimann A, Stern D, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv 2016; 9(21): 2200-9.
[33]
Gonska B, Seeger J, Keßler M, von Keil A, Rottbauer W, Wöhrle J. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. Clin Res Cardiol 2017; 106(8): 590-7.
[34]
Petronio AS, Sinning JM, Van Mieghem N, et al. Optimal implantation depth and adherence to guidelines on permanent pacing to improve the results of transcatheter aortic valve replacement with the medtronic corevalve system: The corevalve prospective, international, post-market ADVANCE-II study. JACC Cardiovasc Interv 2015; 8(6): 837-46.
[35]
Katsanos S, van Rosendael P, Kamperidis V, et al. Insights into new-onset rhythm conduction disorders detected by multi-detector row computed tomography after transcatheter aortic valve implantation. Am J Cardiol 2014; 114(10): 1556-61.
[36]
Nishiyama T, Tanosaki S, Tanaka M, et al. Predictive factor and clinical consequence of left bundle-branch block after a transcatheter aortic valve implantation. Int J Cardiol 2017; 227: 25-9.
[37]
Lange P, Greif M, Vogel A, et al. Reduction of pacemaker implantation rates after CoreValve(R) implantation by moderate predilatation. EuroIntervention 2014; 9(10): 1151-7.
[38]
Nombela-Franco L, Rodés-Cabau J, DeLarochellière R, et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv 2012; 5(5): 499-512.
[39]
Amat-Santos IJ, Dahou A, Webb J, et al. Comparison of hemodynamic performance of the balloon-expandable SAPIEN 3 versus SAPIEN XT transcatheter valve. Am J Cardiol 2014; 114(7): 1075-82.
[40]
Daneault B, Koss E, Hahn RT, et al. Efficacy and safety of postdilatation to reduce paravalvular regurgitation during balloon-expandable transcatheter aortic valve replacement. Circ Cardiovasc Interv 2013; 6(1): 85-91.
[41]
Franzoni I, Latib A, Maisano F, et al. Comparison of incidence and predictors of left bundle branch block after transcatheter aortic valve implantation using the CoreValve versus the Edwards valve. Am J Cardiol 2013; 112(4): 554-9.
[42]
Willson AB1, Webb JG, Labounty TM, et al. 3-dimensional aortic annular assessment by multidetector computed tomography predicts moderate or severe paravalvular regurgitation after transcatheter aortic valve replacement: A multicenter retrospective analysis. J Am Coll Cardiol 2012; 59(14): 1287-94.
[43]
Schroeter T, Linke A, Haensig M, et al. Predictors of permanent pacemaker implantation after Medtronic CoreValve bioprosthesis implantation. Europace 2012; 14(12): 1759-63.
[44]
Leber AW, Eichinger W, Rieber J, et al. MSCT guided sizing of the Edwards Sapien XT TAVI device: Impact of different degrees of oversizing on clinical outcome. Int J Cardiol 2013; 168(3): 2658-64.
[45]
Husser O, Pellegrini C, Kessler T, et al. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 2016; 9(3): 244-54.
[46]
Blanke P, Pibarot P, Hahn R, et al. Computed tomography-based oversizing degrees and incidence of paravalvular regurgitation of a new generation transcatheter heart valve. JACC Cardiovasc Interv 2017; 10(8): 810-20.
[47]
Erkapic D, De Rosa S, Kelava A, Lehmann R, Fichtlscherer S, Hohnloser SH. Risk for permanent pacemaker after transcatheter aortic valve implantation: a comprehensive analysis of the literature. J Cardiovasc Electrophysiol 2012; 23: 391-7.
[48]
Akin I, Kische S, Paranskaya L, et al. Predictive factors for pacemaker requirement after transcatheter aortic valve implantation. BMC Cardiovasc Disord 2012; 12: 87.
[49]
Boerlage-Van Dijk K, Kooiman KM, Yong ZY, et al. Predictors and permanency of cardiac conduction disorders and ne- cessity of pacing after transcatheter aortic valve implantation. Pacing Clin Electrophysiol 2014; 37: 1520-9.
[50]
Testa L, Latib A, De Marco F, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValve Revalving System. Circulation 2013; 127: 1300-7.
[51]
Houthuizen P, van der Boon RM, Urena M, et al. Occurrence, fate and consequences of ventricular conduction abnormalities after transcatheter aortic valve implantation. EuroIntervention 2014; 9(10): 1142-50.
[52]
Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol 2012; 60(18): 1743-52.
[53]
Toggweiler S, Stortecky S, Holy E, et al. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree av block and the need for telemetry monitoring. JACC Cardiovasc Interv 2016; 9(12): 1269-76.
[54]
Bagur R, Rodés-Cabau J, Gurvitch R, et al. Need for permanent pacemaker as a complication of transcatheter aortic valve implantation and surgical aortic valve replacement in elderly patients with severe aortic stenosis and similar baseline electrocardiographic findings. JACC Cardiovasc Interv 2012; 5(5): 540-51.
[55]
Chorianopoulos E, Krumsdorf U, Pleger ST, Katus HA, Bekeredjian R. Incidence of late occurring bradyarrhythmias after TAVI with the self-expanding CoreValve(®) aortic bioprosthesis. Clin Res Cardiol 2012; 101(5): 349-55.
[56]
Nazif TM, Dizon JM, Hahn RT, et al. PARTNER Publications Office. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: The PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv 2015; 8(1 Pt A): 60-9.
[57]
Pereira E, Ferreira N, Caeiro D, et al. Transcatheter aortic valve implantation and requirements of pacing over time. Pacing Clin Electrophysiol 2013; 36(5): 559-69.
[58]
Urena M, Webb JG, Tamburino C, et al. Permanent pacemaker implantation after transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation 2014; 129(11): 1233-43.
[59]
Sawaya FJ, Spaziano M, Lefèvre T, et al. Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience. World J Cardiol 2016; 8(12): 735-45.
[60]
van der Boon RM, Van Mieghem NM, Theuns DA, et al. Pacemaker dependency after transcatheter aortic valve implantation with the self-expanding Medtronic CoreValve System. Int J Cardiol 2013; 168(2): 1269-73.
[61]
Naveh S, Perlman GY, Elitsur Y, et al. Electrocardiographic predictors of long-term cardiac pacing dependency following transcatheter aortic valve implantation. J Cardiovasc Electrophysiol 2017; 28(2): 216-23.
[62]
Renilla A, Rubín JM, Rozado J, Moris C. Long-term evolution of pacemaker dependency after percutaneous aortic valve implantation with the corevalve prosthesis. Int J Cardiol 2015; 201: 61-3.
[63]
Perrin N, Perrin T, Hachulla AL, et al. Conduction disorders using the Evolut R prosthesis compared with the CoreValve: has anything changed? Open Heart 2018; 5(1): e000770.
[64]
Meredith Am IT, Walters DL, Dumonteil N, et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol 2014; 64(13): 1339-48.
[65]
Siontis GC, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: A meta-analysis. J Am Coll Cardiol 2014; 64(2): 129-40.
[66]
Buellesfeld L, Stortecky S, Heg D, et al. Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 60(6): 493-501.
[67]
Latsios G, Gerckens U, Buellesfeld L, et al. “Device landing zone” calcification, assessed by MSCT, as a predictive factor for pacemaker implantation after TAVI. Catheter Cardiovasc Interv 2010; 76(3): 431-9.
[68]
Abramowitz Y, Kazuno Y, Chakravarty T, et al. Concomitant mitral annular calcification and severe aortic stenosis: Prevalence, characteristics and outcome following transcatheter aortic valve replacement. Eur Heart J 2017; 38(16): 1194-203.
[69]
Toutouzas K, Synetos A, Tousoulis D, et al. Predictors for permanent pacemaker implantation after core valve implantation in patients without preexisting ECG conduction disturbances: The role of a new echocardiographic index. Int J Cardiol 2014; 172(3): 601-3.
[70]
Schewel D, Schewel J, Schlüter M, et al. Correlation of tricuspid regurgitation and new pacemaker implantation in patients undergoing transcatheter aortic valve implantation. Int J Cardiol 2018; 261: 37-41.
[71]
Spaziano M, Chieffo A, Watanabe Y, et al. WIN-TAVI Investigators. Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. J Cardiovasc Comput Tomogr 2018; 12(4): 338-43.
[72]
Breithardt G, Breithardt OA. Left bundle branch block, an old-new entity. J Cardiovasc Transl Res 2012; 5(2): 107-16.
[73]
Maeno Y, Abramowitz Y, Kawamori H, et al. A Highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging 2017; 10: 1139-47.
[74]
Abramowitz Y, Kazuno Y, Chakravarty T, et al. Concomitant mitral annular calcification and severe aortic stenosis: prevalence, characteristics and outcome following transcatheter aortic valve replacement. Eur Heart J 2017; 38(16): 1194-203.
[75]
Rodríguez-Olivares R, van Gils L, El Faquir N, et al. Importance of the left ventricular outflow tract in the need for pacemaker implantation after transcatheter aortic valve replacement. Int J Cardiol 2016; 216: 9-15.
[76]
Guetta V, Goldenberg G, Segev A, et al. Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve Revalving System. Am J Cardiol 2011; 108(11): 1600-5.
[77]
Zaman S, McCormick L, Gooley R, et al. Incidence and predictors of permanent pacemaker implantation following treatment with the repositionable Lotus™ transcatheter aortic valve. Catheter Cardiovasc Interv 2017; 90(1): 147-54.
[78]
Salizzoni S, Anselmino M, Fornengo C, et al. One-year follow-up of conduction disturbances following transcatheter aortic valve implantation. J Cardiovasc Med (Hagerstown) 2015; 16(4): 296-302.
[79]
Rivard L, Schram G, Asgar A, et al. Electrocardiographic and electrophysiological predictors of atrioventricular block after transcatheter aortic valve replacement. Heart Rhythm 2015; 12(2): 321-9.
[80]
Badenco N, Chong-Nguyen C, Maupain C, et al. Respective role of surface electrocardiogram and His bundle recordings to assess the risk of atrioventricular block after transcatheter aortic valve replacement. Int J Cardiol 2017; 236: 216-20.
[81]
European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Brignole M, et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy: The task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013; 15: 1070-118.
[82]
van der Boon RM, Nuis RJ, Van Mieghem NM, et al. New conduction abnormalities after TAVI--frequency and causes. Nat Rev Cardiol 2012; 9(8): 454-63.
[83]
Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv 2016; 9: 2189-99.
[84]
Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: The U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol 2011; 58(20): 2130-8.
[85]
Urena M, Webb JG, Cheema A, et al. Impact of new-onset persistent left bundle branch block on late clinical outcomes in patients undergoing transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv 2014; 7(2): 128-36.
[86]
Elmariah S, Palacios IF, McAndrew T, et al. PARTNER Investigators. Outcomes of transcatheter and surgical aortic valve replacement in high-risk patients with aortic stenosis and left ventricular dysfunction: Results from the Placement of Aortic Transcatheter Valves (PARTNER) trial (cohort A). Circ Cardiovasc Interv 2013; 6(6): 604-14.
[87]
Tzikas A, van Dalen BM, Van Mieghem NM, et al. Frequency of conduction abnormalities after transcatheter aortic valve implantation with the Medtronic-CoreValve and the effect on left ventricular ejection fraction. Am J Cardiol 2011; 107(2): 285-9.
[88]
Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, et al. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis. Circ Cardiovasc Interv 2016; 9(5): e003635.
[89]
Pereira E, Ferreira N, Caeiro D, et al. Transcatheter aortic valve implantation and requirements of pacing over time. Pacing Clin Electrophysiol 2013; 36(5): 559-69.
[90]
Buellesfeld L, Stortecky S, Heg D, et al. Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 60(6): 493-501.
[91]
Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv 2016; 9(21): 2189-99.
[92]
Watanabe Y, Kozuma K, Hioki H, et al. Pre-existing right bundle branch block increases risk for death after transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv 2016; 9(21): 2210-6.
[93]
Nalluri N, Atti V, Munir AB, et al. Valve in valve transcatheter aortic valve implantation (ViV-TAVI) versus redo-Surgical aortic valve replacement (redo-SAVR): A systematic review and meta-analysis. J Interv Cardiol 2018; 31(5): 661-71.
[94]
Khawaja MZ, Haworth P, Ghuran A, et al. Transcatheter aortic valve implantation for stenosed and regurgitant aortic valve bioprostheses CoreValve for failed bioprosthetic aortic valve replacements. J Am Coll Cardiol 2010; 55(2): 97-101.
[95]
Neupane S, Singh H, Lämmer J, et al. Meta-analysis of transcatheter valve-in-valve implantation versus redo aortic valve surgery for bioprosthetic aortic valve dysfunction. Am J Cardiol 2018; 121(12): 1593-600.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [205 - 218]
Pages: 14
DOI: 10.2174/1573403X15666181205105821
Price: $58

Article Metrics

PDF: 54
HTML: 2